Is the cost-effectiveness threshold cost-effective in cancer therapy?
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2015, Vol 8, Issue 2
Abstract
Introduction: To compare availability of innovative cancer drugs in countries with established cost-effectiveness threshold (Great Britain, Czech Republic, Sweden and Poland) and where this criterion is not used (Germany, France, Italy), and to assess the relationship between the reimbursement system and the expenditures and health outcomes. Methods: The analysis of reimbursement decisions concerning innovative cancer drugs approved by the European Medicines Agency in the years 2012-2013 and the available data concerning incidence, 5-year relative survival rate and the treatment costs of breast, lung, colon and prostate cancer. Results: The assessment included 19 innovative drugs. Most of them were covered by reimbursement in countries without a cost-effectiveness threshold — 80.7%, compared to the countries with a cost-effectiveness threshold — 59.6% (48.7% including Poland). Three products were financed in all reimbursement systems, with the exception of Poland: Perjeta, Xalkori and Xtandi. In countries without the cost-effectiveness threshold the health outcomes expressed as 5-year relative survival were better compared to EU in general or to most of countries which use the cost-effectiveness threshold, whereas expenditures per capita in most cancers were diversified — large (15-27 €, Germany) or similar to the countries with the cost-effectiveness threshold (6-13 €, France and Italy). In Poland for most evaluated cancers the lowest 5-year relative survival was noted, with the lowest expenditure per capita (5-9 €) simultaneously. Conclusions: The percentage of reimbursed innovative cancer drugs is higher in countries without the cost-effectiveness threshold, where better health outcomes are observed. Limited access to innovative therapies resulting from restrictive financial criteria may have a significant impact on health outcomes in cancer treatment.
Authors and Affiliations
Łukasz Kaczyński, Beata Serafin, Patrycja Prząda-Machno, Marcin Kaczor
Keywords
Related Articles
- EP ID EP192167
- DOI 10.7365/JHPOR.2015.2.6
- Views 107
- Downloads 0
Thrombocytopenia Symptoms and their Impact on Patients Daily Activities assessment Vignette (TSIDAV) – validation of the vignette
Objective: Our aim was to validate the TSIDAV vignette in thrombocytopenia patients. Methods: The vignettes validation was performed during a study on adults and children with thrombocytopenia. The data were collected a...
Association between EQ-5D-3L population norms and gross domestic product based on purchasing power parity in European countries
Background One of the of health-related quality of life (HRQoL) measurement methods is the EQ-5D questionnaire. Population norms of the EQ-5D can be used to compare profiles for patients with specific conditions with da...
Protection of sensitive data in telemedicine services
The article presents security risks related to the use of telemedicine services and technical guidelines for protection of the medical records in terms of their confidentiality, integrity and availability. It also mentio...
Primary immunodeficiencies – epidemiology, spending on therapy, diagnostic and therapeutic needs in Poland
Abstract Primary immunodeficiencies (PID) are a heterogeneous group of over 300 diseases of the immune system characterised by its disfunction, and in consequence by chronic or recurrent infections, autoimmunity, aller...
Severe allergic asthma treatment in Poland
Severe asthma is a heterogeneous disease, which, as it is now believed, requires a personalized therapy dependent on phenotype. Omalizumab, a humanized monoclonal antibody that specifically binds to free immunoglobulin E...